| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.6 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.6 |